Cigna Corp.

Bristol Myers Squibb’s Celgene defrauded the US Patent Office, filed baseless lawsuits and used illicit reverse-payment settlements to “unlawfully extend, and continue to extend, a monopoly” for its P

After three years, Amgen has to pay Regeneron Pharmaceuticals more than $400m in damages after a federal court jury found the biotech liable for violating antitrust and tort laws by allegedly using ag

When the Federal Trade Commission (FTC) officially accused the three largest PBMs of artificially inflating insulin prices, it marked the latest move in what has become a protracted effort by federa

Ever since biosimilar competition to AbbVie Inc. 's Humira (adalimumab) began to hit the US market in early 2023, all eyes have been on the uptake of off-patent rivals, given that the product represe